Treatment of severe refractory erythema nodosum leprosum with tumor necrosis factor inhibitor Etanercept

Sundeep Chowdhry; Akhilesh Shukla; Paschal D'souza; Tapan Dhali; Prashansa Jaiswal

doi:10.1016/j.ijmyco.2016.02.002

Treatment of severe refractory erythema nodosum leprosum with tumor necrosis factor inhibitor Etanercept

Int J Mycobacteriol. 2016 Jun;5(2):223-5. doi: 10.1016/j.ijmyco.2016.02.002. Epub 2016 Feb 24.

Authors

Sundeep Chowdhry¹, Akhilesh Shukla², Paschal D'souza¹, Tapan Dhali¹, Prashansa Jaiswal¹

Affiliations

¹ Department of Dermatology, Venereology, and Leprology, ESI-Postgraduate Institute of Medical Sciences and Research, New Delhi, India.
² Department of Dermatology, Venereology, and Leprology, ESI-Postgraduate Institute of Medical Sciences and Research, New Delhi, India. Electronic address: drakhilesh89@gmail.com.

PMID: 27242236
DOI: 10.1016/j.ijmyco.2016.02.002

Abstract

Erythema nodosum leprosum (ENL) is a common complication of lepromatous leprosy. Some patients unresponsive to conventional, first-line therapeutics develop recurrent, recalcitrant ENL. Here, we report a case of severe refractory ENL that was successfully treated with Etanercept. Biologics may be considered as therapeutic alternatives in management of severe, recalcitrant ENL.

Keywords: Biologics; Erythema nodosum leprosum; Etanercept; Leprosy; Treatment.

Publication types

Case Reports

MeSH terms

Erythema Nodosum / drug therapy*
Erythema Nodosum / etiology
Erythema Nodosum / metabolism
Etanercept / administration & dosage*
Humans
Leprosy / complications*
Male
Middle Aged
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Tumor Necrosis Factor-alpha / metabolism

Substances

Tumor Necrosis Factor-alpha
Etanercept